A Phase 3 interventional study of Tabirafusp tedromer and Aflibercept (2.0 mg) in Diabetic Macular Edema (DME), sponsored by Kodiak Sciences Inc. Recruiting at 52 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Kodiak Sciences Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.
Among the 276 studies in Macular Edema with a site in United States, this one is the 11th largest by planned enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2026, is one of 50 in phase 3, reaches primary completion later than 27 of the 31 other live ones, and was the 274th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Puerto Rico
Ages 18+
Genentech, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 101 · Phase 3 57 · Phase 4 33
First in 1992; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 910 is above the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 45 across the 244 interventional studies, 60 across the 30 observational. Of the 223 that completed or were terminated, 131 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 276 have an industry lead sponsor. The 10 most frequent:
Kodiak Sciences Inc is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Kodiak Sciences Inc has 6 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Edema with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06957080Phase 3EyeBiotech Ltd.A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | 2027-01-11 |
| NCT06996080Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | 2027-02 |
| NCT06990399Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | 2027-04 |
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT07449923Phase 3EyePoint Pharmaceuticals, Inc.CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | 2027-10 |
Add all 11 to your calendar (.ics) → With an account.
Among the 276 studies in Macular Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravitreal injection of tabirafusp tedromer once every 4 weeks for 6 monthly doses followed by every-8-week dosing with additional individualized dosing (up to monthly dosing)
Drug: Tabirafusp tedromer
Intravitreal injection of tabirafusp tedromer once every 4 weeks for 6 monthly doses followed by individualized dosing every 4 to 24 weeks.
Drug: Tabirafusp tedromer
Intravitreal injection of aflibercept once every 4 weeks for 5 monthly doses followed by every-8-week dosing
Drug: Aflibercept (2.0 mg)
Intravitreal injection
Also known as: KSI-501
Intravitreal injection
Also known as: Eylea
Best corrected visual acuity (BCVA)
Mean change in BCVA from Day 1 to Year 1
Time frame: Week 52
Started Aug 2026 (actual). Primary completion is estimated for Aug 2028, 24 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's planned 24 months is close to that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kodiak Sciences Inc